HPD Research Day | February 16, 2018

16 subjects met inclusion criteria and 33.2% were on antidepressants. Seventy-seven percent of patients on treatment had not been followed by a specialist. Univariate analysis determined that those using antidepressants were 7.11 times more likely to have seen a MHP (23% v. 8%, p Conclusion. Diabetes patients with depression symptoms are generally not being monitored by a MHP, unless they are receiving medications. However, the majority of those on medications are not regularly followed by a MPH. Monitoring by a MHP should be the standard of care regardless of medication use. Videoconferencing: Broadcast from Morris Auditorium to regional campuses. Morris Auditorium 11:45 a.m. – 12:15 p.m. Nucleotide Excision Repair Identifies Two Distinct Types of Non-Tumor Adjacent Breast in Sporadic, Non- Germline Breast Cancer Manasi R. Pimpley, BS, Ph.D. in Pharmacy, College of Pharmacy, Nova Southeastern University Jennifer M. Johnson, College of Pharmacy, Thomas Jefferson University Hospital Stephen G. Grant, Ph.D., Project Director, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University Jean J. Latimer, Ph.D., Associate Professor, College of Pharmacy, Nova Southeastern University Objective. Establish molecular temporal scheme for changes leading to breast cancer using Nucleotide Excision Repair (NER) capacity of early stage tumors and their isogenically matched non-tumor adjacent (NTA) samples. Background. Loss of DNA repair capacity leads to genomic instability, a hallmark of carcinogenesis. Sporadic stage I breast tumors are intrinsically deficient in their NER capacity relative to non-diseased breast, the regulation of which is thought to be primarily epigenetic. We previously identified two groups of NTA tissue explants based on their NER capacities as measured by the functional Unscheduled DNA Synthesis (UDS) assay. 25% of NTA had normal NER capacity, similar to that of BRE, but higher than their matched stage I tumors (High-Low pair), whereas 75% exhibited lower NER capacity relative to BRE and similar to the matched tumor (Low-Low pair). We hypothesized that epigenetic regulation of NER genes would explain these different types of NTA. Methods. The functional UDS assay was used to select cell line pairs established by the Latimer Lab’s tissue engineering system, representing the two groups. Expression of 20 canonical NER genes was measured by microarray analyses and confirmed with RNA sequencing. Results. The expression pattern of NER genes was concordant with their NER capacity in both types NTA and tumors. RNA sequencing confirmed these findings. Conclusion. The NTA breast represents a preneoplastic stage in breast carcinogenesis. Two different types of NTA have been identified with regard to DNA repair. Grants. NSU’s PFRDG (6/1/12–5/31/14), NIH R29 (PI: Jean Latimer), NSU’s PFRDG (6/1/13-5/31/15). Videoconferencing: Broadcast from Morris Auditorium to regional campuses. Morris Auditorium 2:15 – 2:45 p.m. National Level Exploratory Analysis of Hospital Adverse Drug Events Using the ADE Action Plan as a Framework Fatimah Sherbeny, PharmD, Ph.D. in Pharmacy Student, College of Pharmacy, Nova Southeastern University Julie Lamoureux Barry A. Bleidt, Ph.D., Professor, College of Pharmacy, Nova Southeastern University Objective. This study was conducted to provide a national level analysis of hospital adverse drug events (ADEs) related to anticoagulants, diabetes agents, and opioids. Background. Hospital ADEs comprised the largest category of adverse events with an estimation of one event per patient per day in hospital care. Based on national ADE data, three types of adverse events were common, clinically significant, preventable, measurable, and were selected as high-priority targets of the ADE Action Plan. The targeted medication classes were anticoagulants, diabetes agents, and opioids. Methods. This study was an exploratory, quantitative, retrospective analysis. The National Inpatient Sample database (NIS) was used to explore ADEs yearly number of events (events/year), and ICD-9 codes associated with ADEs were used to identify the study population. Results. The average national events/year of ADEs during 2009-2014 was 44,824/year for anticoagulants, 8,493/year for diabetes agents, and 31,545/year for opioids. However, the number of events/year varied based on patient demographics, payer type and the presence of different comorbidities. For instance, the national number of events/year was higher in Medicare patients among the three medication classes. Meanwhile, females had lower number of events/year due to anticoagulants and diabetes